Clinical Trial 2018-05-14T10:53:09+00:00

Ayala is evaluating the potential of a new investigation drug, AL101. AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway.

AL101 has completed phase 1 studies and will enter phase 2 in the second half of 2018 for adenoid cystic carcinoma patients with activated Notch pathway.